CTOs on the Move

ID Comms

www.idcomms.com

 
Brands are not getting the media they deserve and are wasting money on things that dont drive business growth. As media gets more complex and fast-changing, its hard to know whats working and what needs improving. Without a clear plan, brands will lose their competitive advantage. Our evidence-based consulting gives brands a framework to remove waste and optimize the value of their media investments. Our clients are able to make more intelligent media decisions so they can trust that their investments will grow their brands. When brands get more value from their media investments they grow. Our #MediaForGrowth Program is designed ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

introlligent

introlligent is a Sacramento, CA-based company in the Business Services sector.

Galasource Inc

Galasource Inc is a Denver, CO-based company in the Business Services sector.

iMed Studios

iMed Studios is a Ames, IA-based company in the Business Services sector.

Highways And Skyways Inc

Highways And Skyways Inc is a Greensboro, NC-based company in the Business Services sector.

Xencor

Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.